Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2024

Commitments And Contingencies Disclosure [Abstract]

Schedule Of Royalty Liability Account Roll Forward

The following table shows the activity within the Royalty Liability account as well as the effective interest rate (dollars in thousands):

Balance, January 1, 2023	$	—
Proceeds from sale of 1% future royalties		150,000
Deferred transaction costs		(4,375	)
Amortization of deferred transaction costs		3
Non-cash interest expense on liability for sale of future royalties		182
Balance, December 31, 2023	$	145,810
Amortization of deferred transaction costs		230
Non-cash interest expense on liability for sale of future royalties		15,942
Royalty revenue earned by or payable to Sagard		(12,337	)
Balance, December 31, 2024	$	149,645
Effective interest rate	8.9% – 11.1%

Schedule of Lease Term and Discount Rate

Financing liability information was as follows (dollars in thousands):

	December 31, 2024		December 31, 2023
Weighted average remaining lease term (in years)		16.8		17.8

Lease information was as follows (dollars in thousands):

	December 31, 2024			December 31, 2023
Operating lease right-of-use assets(1)	$	13,109		$	4,685
Operating lease liability-current(2)	$	2,423		$	1,423
Operating lease liability-long-term		11,645			3,925
Total	$	14,068		$	5,348
Weighted average remaining lease term (in years)		7.1			3.7
Weighted average discount rate		7.3	%		7.3	%

__________________________

(1)Operating right-of-use assets related to vehicles, offices and the manufacturing facility for V-Go are included in other assets in the consolidated balance sheets.

(2)Operating lease liability–current is included in accrued expenses and other current liabilities in the consolidated balance sheets.

Summary of Lease Information

	Year Ended December 31,
	2024		2023		2022
Interest expense	$	9,619	$	9,617	$	9,550
Amortization of debt issuance costs		209		208		208
Interest expense on financing liability	$	9,828	$	9,825	$	9,758

	Year Ended December 31,
	2024		2023		2022
Operating lease costs	$	2,103	$	1,675	$	1,525
Variable lease costs		234		104		274
Cash paid		2,292		1,068		1,823

Summary of Remaining Financing Liability Payments

The Company's remaining financing liability payments were as follows (in thousands):

	December 31, 2024
2025	$	10,269
2026		10,533
2027		10,849
2028		11,174
2029		11,510
Thereafter		165,769
Total		220,104
Interest payments		(113,699	)
Debt issuance costs		(2,466	)
Total financing liability	$	103,939

Remaining Purchase Commitments and Estimated Capacity Fee Liability Requirements

The Company's remaining purchase commitments and estimated capacity fee liability as of December 31, 2024 were as follows (€ in millions):

	December 31, 2024
	Remaining Purchase Commitments		Estimated Capacity Fees
2025		—		1.5
2026(1)		4.1		2.0
2027		6.0		1.0
2028		6.0		1.0
2029		5.8		1.0
2030		5.8		1.0
2031		7.8		0.5
2032		7.7		0.5
2033		7.7		0.5
2034		4.3		0.5
Total		55.2		9.5

__________________________

(1)If there is a delay in the availability of insulin with FDA approved inclusion bodies and supply does not begin in 2026 as currently expected, the Company will incur a capacity fee of €750,000 per quarter that the product is not available for purchase.

Schedule of Future Minimum Office And Vehicle Lease Payments

The Company's future minimum office and vehicle lease payments were as follows (in thousands):

	December 31, 2024
2025	$	3,157
2026		2,579
2027		2,540
2028		2,087
2029		1,485
Thereafter		6,236
Total		18,084
Interest expense		(4,016	)
Total operating lease liability	$	14,068